Literature DB >> 11418489

p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance.

G Guillerm1, E Gyan, D Wolowiec, T Facon, H Avet-Loiseau, K Kuliczkowski, F Bauters, P Fenaux, B Quesnel.   

Abstract

p15(INK4b) and p16(INK4a) proteins are cell cycle regulators involved in the inhibition of G1 phase progression. High frequency of methylation of both genes has been reported in multiple myeloma (MM), but it remains to be determined how and when these alterations contribute to tumorigenesis. Monoclonal gammopathy of undetermined significance (MGUS) represents an early disease stage in a fraction of MMs. Plasma cells from 33 patients with MGUS and 33 patients with MM were isolated and analyzed for p15(INK4b) and p16(INK4a) methylation by methylation-specific polymerase chain reaction. Selective methylation was found in 19% for p16(INK4a), 36% for p15(INK4b), and 6.5% for both genes in MGUS, and frequencies were similar in MM suggesting that methylation of these genes is an early event, not associated with transition from MGUS to MM. p15(INK4b) and p16(INK4a) gene methylation might contribute to immortalization of plasma cells rather than malignant transformation in the natural history of MM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418489     DOI: 10.1182/blood.v98.1.244

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

2.  Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.

Authors:  Chor-Sang Chim; Raymond Liang; Man-Hin Leung; Yok-Lam Kwong
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

3.  Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Hiroshi Handa; Yoshiko Sasaki; Hikaru Hattori; Lobna Alkebsi; Tetsuhiro Kasamatsu; Takayuki Saitoh; Takeki Mitsui; Akihiko Yokohama; Norifumi Tsukamoto; Morio Matsumoto; Hirokazu Murakami
Journal:  Oncol Lett       Date:  2017-07-26       Impact factor: 2.967

4.  Aberrant promoter methylation of p15 (INK⁴b) and p16 (INK⁴a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis.

Authors:  Xuan Wang; Yan-Bin Zhu; Hai-Peng Cui; Ting-Ting Yu
Journal:  Tumour Biol       Date:  2014-06-08

Review 5.  Beyond genetics--the emerging role of epigenetic changes in hematopoietic malignancies.

Authors:  Oliver Galm; Manel Esteller
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

6.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Fenghuang Zhan; Jeffrey Sawyer; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

Review 7.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

Review 8.  Molecular aspects of multiple myeloma.

Authors:  G Pratt
Journal:  Mol Pathol       Date:  2002-10

Review 9.  Molecular biology of myeloma.

Authors:  N C Gutiérrez; R García-Sanz; J F San Miguel
Journal:  Clin Transl Oncol       Date:  2007-10       Impact factor: 3.405

10.  Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma.

Authors:  Roberta Martiniani; Valentina Di Loreto; Chiara Di Sano; Alessandra Lombardo; Anna Marina Liberati
Journal:  Adv Hematol       Date:  2012-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.